Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):129-35

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  BONE METASTASES IN THE ERA OF TARGETED TREATMENTS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):129-35

DOI: 10.23736/S1824-4785.19.03204-7

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Quantitative radionuclide imaging of bone metastases

Stijn DE SCHEPPER 1, Philipp RITT 2, Tim Van den WYNGAERT 1, 3, Torsten KUWERT 2

1 Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium; 2 Clinic of Nuclear Medicine, University-Hospital Erlangen-Nürnberg, Erlangen, Germany; 3 Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium



By improving the localization of foci of pathological tracer uptake and offering information on their computed tomography (CT) morphology, single photon emission computed tomography (SPECT)/CT hybrid imaging has considerably improved the diagnostic accuracy of skeletal scintigraphy. SPECT/CT also has the potential to measure tracer uptake in vivo in absolute units. The present article reviews the methodology for and the potential clinical impact of quantitative skeletal scintigraphy.


KEY WORDS: Tomography, emission-computed, single-photon; Tomography, X-ray Computed; Physics; Radionuclide imaging

top of page